Jon Campbell, PhD, MS
Jon Campbell, PhD, MS is the Chief Science Officer (CSO) of the National Pharmaceutical Council (NPC), which sponsors and conducts research on health policy issues related to the development and use of innovative biopharmaceuticals to improve the health of patients. NPC’s research contributes to the body of evidence that supports discussions and decisions about patient […]
Lisa Prosser, PhD
Dr. Prosser is the Marilyn Fisher Blanch Research Professor of Pediatrics and Director of the Susan B. Meister Child Health Evaluation and Research Center. Her research focuses on measuring the value of childhood health interventions using methods of decision sciences and economics. Current research topics include newborn screening programs, vaccination programs, and methods for valuing […]
Cheryl Neslusan, PhD
Dr. Neslusan is currently Group Director of Market Access Scientific and External Strategy (MAxSES) in the U.S. Value and Evidence Scientific Engagement team at Janssen Scientific Affairs, part of Johnson & Johnson. The MAxSES Team is responsible for U.S. market access scientific strategy for medicines in early development, anticipating future market access trends. In addition, […]
Phil Naughten, PharmD
Phil Naughten, PharmD is the Vice President of the Value and Evidence Generation Function in the medical affairs department of Takeda Pharmaceuticals USA. Currently, his responsibilities include the oversight of U.S.-focused HEOR activities, Clinical Collaborative and ISR research, as well as the field medical team that works with payer organizations. His team concentrates its efforts […]
Russ Montgomery, PhD
Russ Montgomery, PhD is the Senior Director of U.S. Value Assessment Strategy at GSK. In his role, he is responsible for value evidence planning and response to assessments conducted by government agencies and HTA organizations and external engagement on value-related policies and methods best practices. Prior to joining GSK, Russ worked on global value policy […]
Will Cromarty, BA
Will Cromarty is the Manager of Health Policy at the Biotechnology Innovation Organization (BIO), focusing on issues related to value assessment frameworks and implementation of the Inflation Reduction Act’s health policy provisions. He is also responsible for helping the Health Policy team navigate various federal and state health policy matters. Will holds a BA from […]
Randy Burkholder, BA
Randy Burkholder is the Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered healthcare, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value […]